AUTOLUS THERAPEUTICS PLC
Autolus Therapeutics plc is a United Kingdom-based chimeric antigen receptor (CAR) T cell therapy company. The Company is developing programmed T cell therapies for the treatment of cancer. Using its suite of modular T cell programming technologies, the Company is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize cancer cells, break down their defense mechanisms and attack and kill these cells. Its clinical-stage pipeline comprises five programs developed in seven hematological and solid tumor indications. Its clinical-stage programs are Obe-cel (AUTO1), AUTO1/22, AUTO3, AUTO4, and AUTO6. AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. AUTO1/22 is a dual targeting CAR T cell-based therapy candidate based on obe-cel. AUTO3 is for the treatment of B-cell leukemias and lymphomas.
Buy US stocks in Australia starting with AUTL. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in AUTL
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.